Viewing nowPregabalin Capsule 150mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

MFDS item code 201109225 · Approved 2011.10.27 · Insurance code 653402540
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. Additionally, it is effective as an adjunct for partial seizures in patients with epilepsy, applicable in cases with or without secondary general symptoms. It also helps alleviate symptoms of fibromyalgia. Overall, it is widely used for the improvement of neuralgia and myalgia symptoms.
Administer this medicine orally as pregabalin in 2 divided doses per day, with or without food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with renal impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys in unchanged form after entering the systemic circulation. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be given after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Dosing regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to an additional dose given once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behavior, so it is important to closely monitor for mood changes or depressive symptoms during treatment. It should not be taken if there is hypersensitivity to the drug or specific genetic disorders related to lactose intolerance. Diabetic patients should be cautious as weight gain may necessitate adjustments in blood sugar-controlling medication. If symptoms of angioedema occur, such as swelling of the face or around the mouth, you should stop taking this medication immediately and consult a healthcare professional. Elderly patients may be at increased risk of falls due to dizziness or drowsiness caused by this medication. Transient blurred vision or changes in vision may occur; if symptoms persist, consult a doctor. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so doses should be gradually reduced under medical supervision. Patients with a history of substance abuse should be particularly cautious due to the risk of drug misuse. Patients with impaired kidney function may require dose adjustments. Patients with cardiovascular disease should be cautious when taking this medication, and those with severe heart failure should use it with caution. When taken concurrently with opioid analgesics, central nervous system depressant effects may be intensified, so caution is advised. Patients with impaired respiratory function or the elderly should consult healthcare professionals to adjust the dose due to the risk of severe respiratory depression. In early pregnancy, it may pose risks to the fetus; therefore, women who are pregnant or planning to become pregnant should consult a doctor and use effective contraception. Lactating women should consult healthcare professionals regarding the discontinuation of breastfeeding or medication since this drug can be passed into breast milk. It is advisable to avoid hazardous activities such as driving or operating machinery during dizziness or drowsiness after taking this medication. If significant rash or allergic reactions occur during treatment, stop taking this medication immediately and inform your healthcare provider. In the event of overdose, symptoms like confusion, drowsiness, and seizures may appear, and immediate medical attention is necessary.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, respiratory function impairment, dyspnea, rhinitis, neutropenia, increased appetite, anorexia, hypoglycemia, confusion, disorientation, irritability, depression, euphoria, decreased libido, insomnia, depersonalization, paraphilia, restlessness, anxiety, mood swings, emotional blunting, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, motor coordination issues, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, drowsiness, cognitive impairment, nystagmus, speech disorders, myoclonus, reflex reduction, motor abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, tremors at rest, syncope, confusion, motor retardation, olfactory abnormalities, taste loss, writing disabilities, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field deficits, photophobia, dry eyes, conjunctival swelling, vision loss, eye pain, eye fatigue, increased lacrimation, eye irritation, mydriasis, during vibration, changes in depth perception, strabismus, visual brightness, vertigo, hyperacusis, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensation reduction, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urine, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, breast hyperplasia, peripheral edema, edema, gait abnormalities, falls, a feeling of drunkenness, altered sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headaches, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, sleepiness, confusion, depression, agitation, restlessness, seizures, shock, symptoms resembling anaphylaxis, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is best stored at room temperature between 15 and 30 degrees Celsius. This storage method helps maintain the efficacy of the medication for a longer period.
Hard capsule with a white upper half and a white lower half containing white powder that is white or pale yellow.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.